公开(公告)号：US20110183997A1

公开(公告)日：2011-07-28

申请号：US12918801

申请日：2009-02-20

申请人： Donatella Chianelli ,  Xiaolin LI ,  Xiaodong Liu ,  Jon Loren ,  Valentina Molteni ,  Juliet Nabakka ,  Vince Yeh

发明人： Donatella Chianelli ,  Xiaolin LI ,  Xiaodong Liu ,  Jon Loren ,  Valentina Molteni ,  Juliet Nabakka ,  Vince Yeh

IPC分类号： A61K31/497 ,  C07D471/04 ,  A61K31/4375 ,  C12N9/99 ,  A61P29/00 ,  A61P11/08 ,  A61P35/00 ,  A61P37/08 ,  A61P33/02 ,  A61P37/06 ,  A61P3/00 ,  A61P25/00 ,  A61P25/28 ,  A61P25/04 ,  A61P25/30 ,  A61P9/00 ,  A61P9/12 ,  A61P35/02 ,  A61P11/06 ,  A61P11/02 ,  A61P17/00 ,  A61P19/02 ,  A61P1/00 ,  A61P13/12 ,  A61P3/04 ,  A61P3/10 ,  A61P25/24 ,  A61P25/22 ,  A61P25/18 ,  A61P25/16

CPC分类号： C07D471/04

摘要： The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

摘要翻译： 本发明提供了一类新颖的式I化合物：（I）包含这些化合物的药物组合物，用于治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFRα异常活化的疾病或病症，以及 PDGFR＆bgr 激酶。

公开(公告)号：US20140228347A1

公开(公告)日：2014-08-14

申请号：US14258963

申请日：2014-04-22

申请人： Valentina MOLTENI ,  Hank Michael James PETRASSI ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Juliet NABAKKA ,  Bao NGUYEN ,  Vince YEH

发明人： Valentina MOLTENI ,  Hank Michael James PETRASSI ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Juliet NABAKKA ,  Bao NGUYEN ,  Vince YEH

IPC分类号： C07D498/04 ,  C07D491/044 ,  C07D491/107 ,  C07D471/04

CPC分类号： C07D491/107 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048 ,  C07D498/04

摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

摘要翻译： 本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调激酶活性相关的病症的方法。 在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFR＆bgr））激酶的异常活化的疾病或病症的方法。

公开(公告)号：US20130059846A1

公开(公告)日：2013-03-07

申请号：US13595575

申请日：2012-08-27

申请人： Vince YEH ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Valentina MOLTENI ,  Juliet NABAKKA ,  Bao NGUYEN ,  Hank Michael James PETRASSI

发明人： Vince YEH ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Valentina MOLTENI ,  Juliet NABAKKA ,  Bao NGUYEN ,  Hank Michael James PETRASSI

IPC分类号： A61K31/437 ,  A61K31/496 ,  A61K31/5377 ,  A61P19/04 ,  A61P11/00 ,  A61P1/00 ,  A61P37/06 ,  A61P3/00 ,  A61P21/00 ,  A61P17/00 ,  A61P9/12 ,  A61P11/06 ,  A61P37/08 ,  A61P9/00 ,  A61P3/10 ,  C07D471/04

CPC分类号： C07D471/04

摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

公开(公告)号：US20130059832A1

公开(公告)日：2013-03-07

申请号：US13598213

申请日：2012-08-29

申请人： Valentina MOLTENI ,  Hank Michael James PETRASSI ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Juliet NABAKKA ,  Bao NGUYEN ,  Vince YEH

发明人： Valentina MOLTENI ,  Hank Michael James PETRASSI ,  Xiaolin LI ,  Xiaodong LIU ,  Jon LOREN ,  Juliet NABAKKA ,  Bao NGUYEN ,  Vince YEH

IPC分类号： A61K31/437 ,  C07D491/048 ,  A61K31/4545 ,  A61K31/5377 ,  C07D491/107 ,  A61K31/496 ,  A61P11/00 ,  A61P29/00 ,  A61P1/00 ,  A61P3/00 ,  A61P37/00 ,  A61P17/00 ,  A61P9/12 ,  A61P11/06 ,  A61P11/02 ,  A61P37/08 ,  A61P3/10 ,  A61P7/00 ,  A61P1/16 ,  C07D471/04

CPC分类号： C07D491/107 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048 ,  C07D498/04

摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

公开(公告)号：US20240141398A1

公开(公告)日：2024-05-02

申请号：US18279596

申请日：2022-04-08

申请人： Jianhua ZHU ,  Xiaolin Li

发明人： Jianhua ZHU ,  Xiaolin LI ,  Jinghua ZENG

IPC分类号： C12P19/08 ,  A23L33/135 ,  A23L33/21 ,  C12N1/20 ,  C12N9/46 ,  C12P19/14 ,  C12R1/00

CPC分类号： C12P19/08 ,  A23L33/135 ,  A23L33/21 ,  C12N1/205 ,  C12N9/2454 ,  C12P19/14 ,  C12N2500/12 ,  C12N2500/34 ,  C12N2500/74 ,  C12N2523/00 ,  C12R2001/00

摘要： A production method of low molecular weight α-glucan includes: inoculating an activated Leuconostoc mesenteroides in a 5 L fermentor at a 10% inoculum. Fermentation broth is placed in the fermentor at an initial pH of 6.8-7.0, temperature of 25° C. to 28° C., stirring speed at 120 r/min, and fermented for 20-40 hours. Dextranase is added after 5-30 hours of fermentation at a dosage of 1/10,000 to 5/10,000 by volume. The molecular weight of α-glucan is controlled within 10000D by the amount of enzyme added, and the total fermentation process is about 20-40 hours. After the reaction is terminated, the fermentation liquid is concentrated and dried to prepare dietary fiber products with a molecular weight of 500-5000D. The viscosity of the fermentation liquid and concentration of α-glucan in the fermentation liquid may be reduced to promote the forward reaction, accelerate the sucrose conversion rate and increase the product yield.